Internal Medicine, Medical Oncology · San Antonio, TX
NPI
1265459168
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
4383 Medical Dr
San Antonio, TX, 78229
Phone (210) 593-5700
Groups this clinician bills Medicare through
Medicare paid, 2024
$8.3M
371,657 services
Medicare patients, 2024
355
Average age 76
Drug cost, 2024
$3.9M
1,574 prescriptions
Company payments, 2025
$2,089
From 33 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ronald L Drengler was code J9299 (injection, nivolumab, 1 mg), 71,260 times for 38 patients. In total Ronald L Drengler billed 371,657 services in 189 codes, and Medicare paid $8.3M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-07-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9299 Injection, nivolumab, 1 mg | Office | 71,260 | 38 | $24.59 | $1.8M |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 32,706 | 22 | $0.05 | $1,795 |
| J1449 Injection, eflapegrastim-xnst, 0.1 mg | Office | 22,968 | 47 | $20.78 | $477K |
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 21,750 | 14 | $0.86 | $19K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 19,600 | 15 | $44.74 | $877K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 18,450 | 40 | $0.11 | $2,015 |
| J9259 Injection, paclitaxel protein-bound particles (american regent), not therapeutically equivalent to j9264, 1 mg | Office | 16,706 | 11 | $12.25 | $205K |
| J0897 Injection, denosumab, 1 mg | Office | 8,040 | 20 | $20.56 | $165K |
| J0185 Injection, aprepitant, 1 mg | Office | 5,330 | 16 | $1.38 | $7,375 |
| J9228 Injection, ipilimumab, 1 mg | Office | 5,150 | 15 | $136.87 | $705K |
| J0461 Injection, atropine sulfate, 0.01 mg | Office | 4,660 | 17 | $0.07 | $304 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 4,392 | 73 | $0.09 | $387 |
| Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2,720 | 16 | $5.77 | $16K |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 1,900 | 18 | $16.37 | $31K |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 1,900 | 34 | $0.07 | $133 |
By year: 2022 $5.9M for 238,641 services; 2023 $6.6M for 308,115 services; 2024 $8.3M for 371,657 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83615 Clinical Chemistry | 1,424 | 269 | $5.89 | $8,389 |
| 80053 Clinical Chemistry | 1,301 | 251 | $10.30 | $13K |
| 85025 Blood Count | 1,149 | 243 | $7.59 | $8,722 |
| 36415 Venipuncture Blood Collection | 1,069 | 276 | $8.63 | $9,230 |
| 82378 Clinical Chemistry | 328 | 95 | $18.58 | $6,094 |
| 83735 Clinical Chemistry | 328 | 76 | $6.53 | $2,142 |
| 86301 Immunoassay | 280 | 71 | $20.24 | $5,668 |
| 84439 Clinical Chemistry | 255 | 102 | $8.81 | $2,245 |
| 85027 Blood Count | 192 | 74 | $6.31 | $1,211 |
| 82550 Clinical Chemistry | 174 | 73 | $6.38 | $1,110 |
Medicare prescription drug claims, 2024
In 2024, the drug Ronald L Drengler prescribed most often to Medicare patients was Hydrocodone-Acetaminophen (Hydrocodone/Acetaminophen), with 86 prescriptions and refills. In total Ronald L Drengler wrote 1,574 Medicare prescriptions that cost $3.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 86 | 86 | 33 | $3,391 |
| Prednisone Generic | 80 | 102 | 34 | $637 |
| Levothyroxine Sodium Generic | 74 | 97 | 18 | $437 |
| Prochlorperazine Maleate Generic | 72 | 72 | 61 | $1,134 |
| Sancuso Granisetron | 65 | 65 | 30 | $78K |
| Ondansetron Odt Ondansetron | 55 | 56 | 40 | $1,264 |
| Ondansetron Hcl Generic | 54 | 54 | 40 | $717 |
| Eliquis Apixaban | 50 | 53 | 13 | $30K |
| Lidocaine-Prilocaine Lidocaine/Prilocaine | 47 | 47 | 43 | $485 |
| Dexamethasone Generic | 45 | 49 | 20 | $594 |
| Olanzapine Generic | 40 | 40 | 11 | $452 |
| Cabometyx Cabozantinib S-Malate | 34 | 34 | Under 11 | $799K |
| Gabapentin Generic | 33 | 35 | 13 | $264 |
| Potassium Chloride Generic | 33 | 43 | 14 | $597 |
| Tagrisso Osimertinib Mesylate | 30 | 30 | Under 11 | $494K |
Brand drugs: - claims; generic drugs: 1,147 claims; opioid claims: 157.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ronald L Drengler $2,089 ($2,089 in general payments such as food, travel and fees) from 33 companies. The largest payer was Pfizer Inc. with $432.
| Company | Payments | Amount |
|---|---|---|
| Pfizer Inc. PFE | 12 | $432 |
| Galvanize Therapeutics, Inc | 1 | $164 |
| Celgene Corporation BMY | 7 | $161 |
| E.R. Squibb & Sons, L.L.C. BMY | 6 | $151 |
| Janssen Biotech, Inc. JNJ | 6 | $126 |
| Merck Sharp & Dohme LLC MRK | 5 | $124 |
| Immunocore Limited IMCR | 1 | $112 |
| Incyte Corporation INCY | 3 | $69.2 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $66.42 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 2 | $62.13 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.